Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries
Martin WG Brinkhof, François Dabis, Landon Myer, David R Bangsberg, Andrew Boulle, Denis Nash, Mauro Schechter, Christian Laurent, Olivia Keiser, Margaret May, Eduardo Sprinz, Matthias Egger, Xavier Anglaret, for the ART-LINC of IeDEA collaboration
Volume 86, Number 7, July 2008, 559-567
Table 4. Programme factors associated with the three study outcomes in the first 6 months after starting ART
| Programme factors | No follow-up |
Initially followed-up, then lost |
Death |
|||||
|---|---|---|---|---|---|---|---|---|
| Odds ratioa(95% CI) | P-valueb | Hazard ratioa(95% CI) | P-valueb | Hazard ratioa(95% CI) | P-valueb | |||
| 0.055 | 0.46 | 0.031 | ||||||
| Free of charge | 1 | 1 | 1 | |||||
| Fee for service | 3.71 (0.97–16.05) | 1.69 (0.42–6.77) | 4.64 (1.11–19.41) | |||||
| 0.58 | 0.21 | 0.035 | ||||||
| Passive | 1 | 1 | 1 | |||||
| Active | 0.66 (0.15–2.92) | 0.41 (0.10–1.66) | 5.15 (1.16–22.79) | |||||
ART, antiretroviral therapy; CI, confidence interval.a Odds ratios were calculated using multivariable random-effects logistic regression, and hazard ratios were calculated using multivariable Weibull proportional hazard models incorporating the competing risks of death and loss to follow-up. Models were adjusted for the variables listed in Table 4 and for age, sex, year of starting ART, initial ART regimen, baseline CD4-cell count and clinical stage.b P-values were calculated using the Wald test.